Atea Pharmaceuticals, Inc. (AVIR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.83+0.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · AVIR
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | — | — | — | — | — | 351.4 | 48.6 |
| Operating Expenses & Income | |||||||
| R&D Expenses | 155.4 | 148.0 | 144.1 | 114.2 | 81.9 | 167.2 | 38.0 |
| Operating Income | (183.6) | (180.9) | (193.0) | (164.2) | (130.7) | 138.4 | (11.0) |
| Earnings from Continuing Operations | |||||||
| EBT, Incl. Unusual Items | (171.8) | (164.5) | (167.5) | (134.9) | (119.5) | 138.6 | (10.9) |
| Income Tax Expense | (6.5) | (6.2) | 0.9 | 1.0 | (3.6) | 17.4 | — |
| Net Income | |||||||
| Net Income | (164.9) | (158.3) | (168.4) | (136.0) | (116.0) | 121.0 | (10.9) |
| Per Share | |||||||
| Basic EPS | (2.06) | (1.94) | (2.00) | (1.63) | (1.39) | 1.46 | (0.51) |
| Diluted EPS | (2.06) | (1.94) | (2.00) | (1.63) | (1.39) | 1.37 | (0.51) |
| Basic Weighted Avg Shares | 80.1 | 81.5 | 84.3 | 83.4 | 83.2 | 82.8 | 21.6 |
| Diluted Weighted Avg Shares | 80.1 | 81.5 | 84.3 | 83.4 | 83.2 | 88.2 | 21.6 |
| Supplemental | |||||||
| EBITDA | — | (180.5) | (192.5) | (163.7) | (130.4) | 138.4 | (11.0) |
| EBIT | (183.6) | (180.9) | (193.0) | (164.2) | (130.7) | 138.4 | (11.0) |
| Effective Tax Rate | 3.8% | — | — | -0.8% | 3.0% | 12.6% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.